Hypoxia-inducible factor-2α regulates the expression of TRAIL receptor DR5 in renal cancer cells

S.Mahajan1, V.Dammai1, T.Hsu1 and A.S.Kraft1,*
1Hollings Cancer Center and 2Department of Pathology and Laboratory Medicine, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA
*To whom correspondence should be addressed. Tel: +1 843 792 8284; Fax: +1 843 792 9456; Email: kraft@musc.edu

To understand the role of hypoxia-inducible factor (HIF)-2α in regulating sensitivity of renal cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, we transfected wild-type and mutant von Hippel Lindau (VHL) proteins into TRL-absient, VHL-negative A498 cells. We find that wild-type VHL, but not the VHL mutants S65W and C162F that do not degrade HIF proteins, cause TRAIL resistance. Knockdown of the HIF-2α protein by RNA interference (short hairpin RNA) blocked TRAIL-induced apoptosis, decreased the level of TRAIL receptor (DR5) protein and inhibited the transcription of DR5 messenger RNA. By using luciferase constructs containing the upstream region of the DR5 promoter, we demonstrate that HIF-2α stimulates the transcription of the DR5 gene by activating the upstream region between −448 and −1188. Because HIF-2α is thought to exert its effect on gene transcription by interacting with the Max protein partner of Myc in the Myc/Max dimer, small interfering RNAs to Myc were used to lower the levels of this protein. In multiple renal cancer cell lines decreasing the levels of Myc blocked the ability of HIF-2α to stimulate DR5 transcription. PS-341 (VELCADE, bortezomib), a proteasome inhibitor used to treat human cancer increases the level of DR5 in prostate and lung cancer cell lines increased the levels of DR5. Thus, in renal cancer cell lines expressing HIF-2α, this protein plays a role in regulating the levels of the TRAIL receptor DR5.

Introduction

Renal cell carcinoma (RCC) affects >30 000 individuals each year and is responsible for >12 000 deaths (1). These tumors are both radio- and chemoresistant and show minimal therapeutic responses to interleukin-2, interferon γ, tumor-infiltrating lymphocytes and small molecules aimed at inhibiting growth factor receptors, including epidermal growth factor, vascular endothelial growth factor and platelet-derived growth factor receptors (2,3). New therapies are clearly needed to treat renal cancer.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a proapoptotic protein that displays minimal toxicity toward normal cells, both in vitro and in vivo, and kills a wide spectrum of tumor types including renal cancer (4–6). TRAIL binds to two receptors, DR5 (TRAIL-R2) and DR4 (TRAIL-R1) (7), as well as to two receptors that do not conduct an apoptotic signal, DcR1 and DcR2 (8,9). Cytotoxic antibodies, lexatumumab, directed at the TRAIL receptor DR5, when used in an orthotopic metastatic tumor model, decrease the size and metastatic potential of renal tumors that are known to be sensitive to TRAIL in tissue culture (10,11). Resistance to TRAIL in cancer cells, including prostate and multiple myeloma, can be overcome by the addition of PS-341, a proteasome inhibitor (12). This agent functions to increase the number of TRAIL receptors both transcriptionally and by preventing their degradation (12). PS-341 also enhances the ability of TRAIL to induce cell death by increasing the levels of Bn3 proteins including Noxa, Bik and Bim (13–15). Thus, TRAIL treatment of renal cancer offers a novel approach to treating this disease.

Although the exact cause of renal cancer is obscure, 60–80% of RCC have biallelic loss/inactivation of von Hippel Lindau (VHL) tumor suppressor gene as a consequence of gross genetic loss, nonsense or missense point mutations and hypermethylation of the VHL locus (16–18). Because VHL functions as part of Skp1/Cul1/F-box like E3 ligase for the hypoxia-inducible factor (HIF) proteins (19,20), deletion of VHL leads to increased levels of HIF-1α, HIF-2α or both proteins. VHL protein has complex functions unrelated to its regulation of HIF proteins including a role in the synthesis and degradation of extracellular cell matrix by affecting the transport of fibronectin (21), in the regulation of cytoskeletal organization and motility through focal adhesion formation and in the translocalization of fibroblast growth factor receptor (22–24). VHL also regulates RNA stability through increasing the level of RNA-binding proteins (25) and messenger RNA (mRNA) transcription, e.g. the tyrosine hydroxylase gene, by directly interacting with transcription factors, e.g. Sp1 (26). The suppression of the nuclear factor-κB pathway by VHL (27) is thought to play a role in regulating the sensitivity of renal cancer cells to varied apoptotic stimuli. However, the mechanism by which VHL and HIF proteins control the sensitivity of renal cancer cells to TRAIL is unknown.

In normoxic conditions following oxygen-dependent prolyl hydroxylation, the HIF proteins are degraded by the proteasome (28). In VHL-defective RCC cells, the HIF system is activated and a constitutively hypoxic pattern of gene expression is observed, including increases in the Bnip3, cyclin D1, transforming growth factor-α and vascular endothelial growth factor (29,30) proteins. In RCC, there is bias toward HIF-2α rather than HIF-1α expression (31), and HIF-1α actually inhibits the action of genes, i.e. β-catenin, that might enhance the growth of certain tumors (32). Overexpression of HIF-2α increases tumor growth, whereas HIF-1α appears to have the reverse effect (31). These two genes have contrasting properties on specific transcription, with HIF-1α positively and HIF-2α negatively regulating the Bel-2-like protein Bnip3 (31). In VHL-defective renal cancer cell lines, cyclin D1 and transforming growth factor-α mRNA are increased by HIF-2α, whereas in this model, HIF-1α had little effect on the expression of these genes (31). Opposite effects on Myc-regulated genes by these two proteins have also been demonstrated (33,34). However, it is not known how or whether HIF proteins regulate sensitivity to TRAIL-induced death.

To better understand how TRAIL might be effectively used to treat renal cancer, we have investigated the role of HIF-2α in the sensitivity of these tumor cells to TRAIL. We find A498 cells that express elevated levels of HIF-2α are sensitive to TRAIL, and overexpression of VHL or expression of a short hairpin RNA (shRNA) that decreases the level of HIF-2α mRNA and protein abrogates this sensitivity. The low or absent levels of HIF-2α decrease the levels of TRAIL receptor DR5 mRNA and protein, explaining the loss of sensitivity.
interfering RNAs (siRNAs) directed at Myc decrease the ability of HIF-2α to stimulate the transcription of this gene in both TRAIL-sensitive and -resistant cell lines, suggesting that these proteins may work independently or co-operatively to regulate HIF-2α. Our data point to the importance of HIF-2α when present in renal and other cancer types in controlling the transcription of the DR5 gene.

Materials and methods

Cell lines and reagents

A498, 786-O, Caki-1 and HK-2 cells were purchased from American Type Culture Collection (Manassas, VA). Cells were maintained in Dulbecco’s modified Eagle (high glucose) medium supplemented with 10% fetal bovine serum. Human VHL and HIF-2α genes were polymerase chain reaction (PCR) cloned into pEGFP-C1 (Clontech, Mountain View, CA) and pCDNA3.0 (Invitrogen, Carlsbad, CA), respectively. The pCDNA3.1 plasmid containing shRNAs targeting HIF-2α (shRNA 1 sense: 5′-GGCTGTGGTTTGTTTCTGG (reverse); Myc-BS5, GCAGGGAAGGAAG (forward) and GAC (forward) and GCGGCTGTACTTTCACTGCC (reverse); Myc-BS3, GGAGTCGATCTGAACCTCAAG (forward) and CTTGAGGTTCAGAGTCCG (reverse); Myc-BS6, GGAACGCTCTTATAGTCT (reverse); Myc-BS2, GCGGAGGATTGCGTTCAAGA (forward) and GGCTGTCACCATGTTCCGT (reverse)) and no shRNA (control) was used to mutate the HIF-2α shRNA target site (nucleotides 2127–2145, GCCGACGTCTGTTATGAAG) using the following next primers: GGAGGCTGCCGGGATCCGCCCCTGGGAAG (mutant forward) and GCCAACGTCGATCTGTTCCGT (mutant reverse). The PCR product was cloned into pGVB2 vector via SacI and NcoI sites and the insert verified by sequencing. The pcDNA3.1/HIF-2α plasmid was used as a template for PCR to mutate the HIF-2α shRNA target site (nucleotides 2127–2145, GCCGACGTCTGTTATGAAG) using the following next primers: GAATTCGCGGCCGCTCAGGTGGCCTGGTCCAGG (wild-type reverse). The PCR fragment was cloned into pCDNA3.1/HIF-2α plasmid and cut with the same restriction enzymes to yield a full-length HIF-2α cDNA clone.

Apoptosis assay

To examine apoptosis, cells were treated with TRAIL for 16 h in growth medium. Flow cytometric analysis was done to detect and quantify apoptosis. Cells were fixed in 70% ethanol and stained with 50 g/ml propidium iodide in 0.1% sodium acetate (pH 5.5), 0.1% (vol/vol) Triton X-100 and 10 mM p-nitrophenyl phosphate. For real-time PCR assay, cells were plated at 3 × 10⁵ per well for 24 h prior to treatment. After 16 h of incubation with PS-341 (500 nM), cells were collected, washed twice with phosphate-buffered saline, incubated at 4°C with phycoerythrin-conjugated antibodies recognizing DR4 and DR5 (eBioscience, San Diego, CA) and then analyzed by flow cytometry.

Luciferase assay

The expression levels of DR4 and DR5 were evaluated by flow cytometry. Total RNA was isolated from A498 cells using RNeasy kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. The first-strand cDNA was synthesized using Superscript first-strand synthesis kit and Oligo (dT) primer (Invitrogen). Relative quantification of DR5 expression was achieved by quantitative real-time PCR (iQ5 optical system) technology (Bio-Rad Laboratories, Hercules, CA) using iQ5 optical system software. The expression level of DR5 was normalized to GAPDH. The primers used for real-time PCR were as follows: DR5 forward ATCCACCAACAAGCATTGAC and reverse TTCTGAGATATGGTGTCCAG and GAPDH forward CAGCTTCAAGATCATAGCA and reverse GTCTCTGGGCTTGGAGAT.

Results

A498 renal cancer cells, which express high levels of HIF-2α and no HIF-1α or VHL, are sensitive to TRAIL-induced apoptosis (11). As...
shown by the appearance of a sub-G$_1$ peak on FACS analysis, the addition of TRAIL to these cells induces apoptosis as early as 4 h, and 100% of cells are dead by 20 h (Figure 1B). To examine the ability of HIF-2α to modulate the sensitivity of A498 renal cancer cells to TRAIL, A498 cells were first transiently transfected with a construct expressing a green fluorescent protein (GFP)–VHL fusion protein and then FACS sorted for the expression of GFP. The overexpression of VHL drives down the level of HIF-2α protein (Figure 2A). The GFP-positive cells were then treated with TRAIL overnight. In comparison with the wild-type cells (Figure 1A), there was no cleavage of caspases, PARP or appearance of a sub-G$_1$ peak on FACS analysis (Figure 2B and C). Transfection of enhanced green fluorescent protein alone did not inhibit the ability of TRAIL to induce apoptosis (supplementary Figure 1A is available at Carcinogenesis Online). In these VHL-transfected cells, we see an increase in the number of cells in the G$_1$ phase of the cell cycle. This result might be secondary to the induction of p27kip1 or to stabilization of p53 (36,37). Specific VHL mutants are expressed in varied tumor types and may or may not function to regulate the HIF proteins. For example, the S65W and C162F mutants are common in RCC, but rarely occur in pheochromocytoma, and these proteins do not induce the degradation of the HIF protein. In comparison, the Y98H and P154L mutant proteins rarely occur in RCC and induce the degradation of HIF (23). As above, these cDNAs were transiently transfected as GFP fusions into

---

**Fig. 1.** Induction of apoptosis in A498 cells by TRAIL. (A) A498 cells were treated with TRAIL (1 μg/ml) at 37°C for 4, 8 and 20 h. Cell lysates collected at each time point were subjected to western blotting using the indicated antibodies. (B) A498 cells treated with TRAIL were harvested at the indicated time points, washed three times with phosphate-buffered saline and fixed with 70% ethanol in phosphate-buffered saline for 2 h at 4°C. Following fixation, cells were stained with propidium iodide as described in Materials and Methods to detect the presence of hypodiploid cells (sub-G$_1$ peak) by flow cytometry.

---

**Fig. 2.** Inhibition of A498 cell death induced by VHL. (A) A498 cells were transfected with pEGFP-C1 (empty vector) or pEGFP-VHL (wild-type) vectors. Forty-eight hours after transfection, cells were washed with phosphate-buffered saline, FACS sorted and enhanced green fluorescent protein (EGFP)-positive cells retained. These cells were lysed and the extract was western blotted with the indicated antibodies. (B) The enhanced green fluorescent protein-sorted cells were grown for 24 h at 37°C before adding TRAIL (1 μg/ml). At the indicated hours of treatment, cells were harvested, lysed in sodium dodecyl sulfate sample buffer and the cleavage of caspase 8, caspase 3 and PARP determined by western blot. (C) A portion of the cells were harvested, washed with phosphate-buffered saline and cell cycle analysis (see legend Figure 1B) done by flow cytometry to detect the presence of a sub-G$_1$ peak.
A498 cells, the cells FACs sorted and then incubated overnight with TRAIL. The transfection of S65W and C162F respond to TRAIL with cell death (supplementary Figure 1B and C is available at Carcinogenesis Online), whereas those VHL mutants that lead to HIF-2α degradation function similarly to wild-type VHL and make these cells insensitive to TRAIL killing (supplementary Figure 1D and E is available at Carcinogenesis Online). Since the level of cell death regulated by the C162F is more extensive than the S65W mutant, it is possible that the latter mutant has a slightly increased ability to degrade HIF-2α protein when compared with C162F, as suggested by the western blot. These experiments suggest that HIF-2α plays a role in regulating TRAIL sensitivity in A498 cells.

To examine the ability of HIF-2α to regulate TRAIL-induced cell death, A498 cells were transfected with a cDNA expression vector encoding HIF-2α shRNA, and five clones were generated that contained markedly decreased levels of HIF-2α (Figure 3A). These clones also expressed decreased levels of the HIF-2α-regulated gene CXCR4. All the clones expressed decreased levels of DR5 protein on western blot (Figure 3A). When incubated with TRAIL, 1 μg/ml, these clones showed resistance to TRAIL-induced killing, whereas the parental cells remained highly sensitive (Figure 3B). To verify that this was not specific to a single shRNA, the experiment was repeated with a second shRNA (see Materials and Methods) with identical results (supplementary Figure 2A and B is available at Carcinogenesis Online). To examine the mechanism of HIF-2α action, we carried out quantitative real-time PCR for DR5 expression on the RNA from wild-type and cells expressing the HIF-2α shRNA. Results from these five clones demonstrated that in the absence of HIF, the levels of DR5 mRNA were markedly decreased (Figure 3C). A498 cells do not express the second TRAIL receptor DR4.

To attempt to determine whether HIF-2α could regulate the transcription of the DR5 gene, promoter constructs containing different regions of the DR5 upstream region in front of a luciferase reporter were transfected into either A498 cells or A498 cells containing a HIF-2α shRNA. We find that in wild-type A498 cells, the region between −448 and −1188 contains sequences that are essential for regulation of the transcription of the DR5 promoter (Figure 4). In comparison, in A498 cells expressing the HIF-2α shRNA, the expression of these identical promoter constructs was markedly diminished (Figure 4). Transfection of HIF-2α into cells with decreased HIF-2α levels overcame the shRNA and stimulated these promoter constructs (Figure 4, but had little effect when transfected into wild-type cells (data not shown). Thus, HIF-2α is capable of regulating transcription of the DR5 promoter.

Recent results from other laboratories demonstrate that HIF-2α functions by stimulating the activity of the Myc protein through interactions with Myc partner proteins, for example Max (33). This observation coupled with the existence of multiple potential E-box-like elements in the upstream region of the DR5 promoter (38), suggested that the HIF-2α effects on the DR5 promoter might be tied to its interaction with Myc and its partners. To examine this possibility, we used both siRNA-targeting Myc and a cDNA chimeric construct that expresses a MadMyc chimera that acts as a dominant-negative protein (39). As predicted by the transcriptional activity of Myc (33), a decrease in this protein (Figure 5A) led to an increase in p21 levels and a decrease in cyclin D2 (Figure 5A). Overexpression of HIF-2α (Figure 5B) in one of the A498 clones expressing the shRNA-targeting HIF-2α increased HIF-2α expression and induced transcription from the DR5 (−1188) promoter (Figure 5B). To carry out these experiments (Figure 5A and B), a mutation was placed in the HIF-2α coding sequence (HIF-2α Mut) so that this mRNA could not be recognized by the shRNA. This stimulation was reversed both by the transfection of Myc siRNA and the dominant-negative MadMyc cDNA construct (Figure 5B), suggesting that the transcriptional regulation of DR5 involved both HIF-2α and Myc proteins. To determine the exact site of c-Myc binding to DR5 promoter, chromatin immunoprecipitation analysis was done focused on seven E-box-like sites identified previously (38), using the known c-Myc-binding site in GAPDH as a control. Results from this experiment demonstrate that the sequence

GTGGAA from −532 to −537 is capable of binding c-Myc when compared with the IgG control. All other sites demonstrated similar binding to the control. To examine whether this site regulated transcriptional activation of the DR5 promoter by c-Myc, it was mutated in the DR5 promoter luciferase construct and this construct was transfected into A498 cells. Mutation of this sequence markedly decreased the baseline activity of the promoter (Figure 5D).
Previously, we have shown that the proteasome inhibitor PS-341, which is used to treat patients with cancer, sensitizes prostate cancer cells to TRAIL-induced cell death by regulating the level of the DR5 receptor mRNA and protein (12). To examine whether the HIF shRNA-containing A498 cells would respond similarly, these cells were treated overnight with TRAIL (1 μg/ml) or PS-341 (0.5 μM) alone or in combination. PS-341 treatment greatly sensitized these cells with low levels of HIF-2α to TRAIL-induced cell death (supplementary Figure 3A is available at Carcinogenesis Online) and, as demonstrated by FACS analysis of two different HIF-2α shRNA-containing clones, this effect is correlated with an increase in TRAIL receptors (supplementary Figure 3B is available at Carcinogenesis Online). Similar results were obtained with MG-132, another proteasome inhibitor (data not shown). As demonstrated by western blots (supplementary Figure 3C is available at Carcinogenesis Online), the increase in DR5 receptors induced by PS-341 is correlated with an increase in both Myc and HIF-2α proteins in both the control and two clones that were examined. This proteasome-induced increase in HIF-2α was reversed when additional siRNA to HIF-2α was transfected into these cells, suggesting that regulation of the level of HIF-2α mRNA might be important to the PS-341 activity.

To examine whether regulation of DR5 transcription by HIF-2α can be generalized to other renal cell cancer cell lines, we studied the effect of siRNA to HIF-2α and Myc on the level of DR5 in PV-10 and RCC4 renal cancer cell lines. Both of these cell lines contain HIF-1α and -2α but no VHL, and in comparison with A498, are relatively insensitive to TRAIL-induced apoptosis. Transfection of HIF-2α siRNA decreased the level of HIF-2α in RCC4 (Figure 6A) and PV-10 (data not shown). Even in the presence of unchanged levels of HIF-1α, a decrease in HIF-2α inhibited the transcription of the DR5 (−1188)-Luc plasmid in both cell lines. Likewise, both Myc siRNA and the MadMyc cDNA transfections decrease the levels of DR5 protein and transcription (Figure 6A and B). To attempt to determine whether HIF-2α was important in other tumor cell lines in controlling DR5 levels, A549 lung and PC3 prostate cancer cell lines were placed in hypoxia to induce an increase in HIF-2α levels (Figure 6C). Western blots demonstrate that this increase in HIF-2α levels was accompanied by a parallel increase in DR5 protein. Knock down of HIF-2α using two different siRNAs inhibited this increase in hypoxia-driven changes in DR5. To evaluate the importance of HIF-1α levels to the control of DR5 transcription, this protein was decreased by two different siRNAs (Figure 6D) and the −1188 DR5 promoter construct was transfected into these cells. In contrast to HIF-2α, lowering the level of HIF-1α did not decrease the luciferase output from the upstream elements of the DR5 promoter (Figure 6E).

Discussion

Our data suggest that HIF-2α protein plays an important role in regulating the levels of DR5 receptors in renal carcinoma cells that express this protein. The ability of HIF-2α to control the level of the TRAIL receptor DR5 does not appear to be limited to TRAIL-sensitive cell lines. siRNAs targeted at HIF-2α decrease the expression of the TRAIL receptor mRNA and protein when transfected into the TRAIL-resistant PV-10 and RCC4 cell lines as well as the TRAIL-sensitive A498 cells. Nor is this effect limited to renal cancer cells since we see similar results in A549 lung and PC3 prostate cancer cell lines when they are placed in hypoxia. In contrast, lowering the level of HIF-1α did not decrease either the level of the DR5 protein or transcription from the DR5 promoter. Additionally, renal cancer Caki cells, which express only VHL, when placed in relative hypoxia induce increased levels of HIF-1α but do not increase either DR5 transcription or protein levels (data not shown). Although HIF-2α plays an important role in regulating the level of DR5, renal cancer cells containing this protein are both sensitive and resistant to TRAIL-induced apoptosis, suggesting that sensitivity to TRAIL is controlled by a complex set of proteins other than the receptor.

Previously, we have shown that PS-341 increases DR5 levels both by inhibiting protein destruction and by increasing DR5 transcription. In renal cancer cells with low HIF-2α levels, we find that PS-341 treatment increases both the level of DR5 protein and sensitivity to TRAIL-induced apoptosis. The effect of this drug is correlated with its ability to increase the levels of both HIF-2α and Myc, two proteins that appear to regulate DR5 transcription. It is possible that PS-341 increases HIF-2α mRNA levels since transfection of siRNA to HIF-2α blocks this compound’s ability to increase protein levels. Trials of PS-341 in humans with renal cancer have yielded varying results. In one study (40), there was little single-agent activity, whereas in a second trial, stable disease was seen in 14 patients with 4 patients having a partial response (41). The combination of PS-341 and TRAIL may have utility in treating renal cancer.

The clear differences between HIF-1α and -2α appear to be found in multiple cell models. Most recently, HIF-1α has been shown to inhibit the function of the Myc protein (34,42). In keeping with the antagonism of Myc, HIF-1α decreases Myc-activated genes including hTERT and BRCA1 (42). HIF-2α has the exact opposite effect (33) enhancing Myc-induced transformation of fibroblasts and promoting cell cycle progression of hypoxic renal carcinoma cells. HIF-1α has been shown to retard tumor growth, whereas HIF-2α stimulates the growth of tumors (31). If in embryonic stem cells the HIF-1α gene is replaced by HIF-2α, the resulting teratoma has increased expression of transforming growth factor-α, vascular endothelial growth factor and cyclin D1 (43). Using microarray analysis, HIF-1α but not HIF-2α has been shown to regulate the levels of glycolytic genes (44). Thus, it is not surprising that HIF-1α and HIF-2α appear to regulate DR5 levels differently. Although there is not a consensus-binding site for HIF-1 (5’GACGTTG3’) (45) in the DR5 promoter, complex regulation of this promoter by HIF-2α and Myc/Max is possible.
Myc protein has been shown to regulate cellular sensitivity to TRAIL through multiple mechanisms. For example, Nieminen et al. (46) found that Myc primed mitochondria by a mechanism involving activation of Bak, enabling weak TRAIL signals to stimulate the mitochondrial pathway. Myc has also been found to decrease the TRAIL-induced increases (47) in Mcl-1 and cIAP2 by inhibition of nuclear factor-κB thus sensitizing the cell to the intrinsic pathway. Increasing the cellular levels of Myc has been shown to upregulate the level of DR5 protein whereas transfection of the dominant-negative MadMyc protein decreases the level of this protein (39). Myc appears to control the transcription of DR5 (39) and there is data to either support an indirect control of transcription (39) or direct control by binding to non-canonical E-boxes (38). We have demonstrated that Myc is capable of binding to the E-box between −532 and −537 in the DR5 promoter and mutation of this site decreases the activity of the DR5 promoter in A498 cells. HIF-2α has been shown to enhance the binding of Myc to gene promoters by increasing the levels of Myc/Max (33) or by directly binding to the E-Box as a HIF-2α–Max complex. Indirect regulation of DR5 transcription could arise from the ability of Myc to control protein synthesis through regulation of ribosomal proteins that may lead to the production of transcription factors that bind to the DR5 promoter [for review see ref. (48)]. HIF is also capable of

Fig. 5. Decreasing Myc protein levels regulates HIF-2α control of DR5 transcription. (A) Western blot of extracts from A498 cells studied in (B) were probed with antibodies to Myc, HIF-2α, p21, cyclin D2 or GAPDH as a loading control. (B) Regulation of DR5 promoter activity in A498 HIF-2α-knockdown cells. A498 cells containing HIF-2α shRNA were transfected with DR5 promoter construct (−1188) with or without the cDNA expressing HIF-2α Mut, MYC siRNA or MadMyc protein were assayed after 48 h. HIF-2α Mut contains a mutation (see Materials and Methods) in the coding sequence so it cannot be recognized by the shRNA. Luciferase activity was obtained using 5 μg of cell protein lysate that was normalized to cotransfected pSV-β-galactosidase plasmid. The luciferase values shown are the mean ± SD from three independent observations. (C) Schematic representation of the human DR5 promoter with seven non-canonical E-box elements is shown. The specific primers for each element used in the PCR in chromatin immunoprecipitation assay are described in the Materials and Methods. The sizes (bp) of the amplified regions for BS1–BS7 are 182, 130, 143, 145, 154 and 112, respectively. A control reaction shown demonstrates c-Myc binding to a known site in GAPDH. The specificity of binding of c-Myc to each site is shown as the fold difference between c-Myc immunoprecipitation and rabbit IgG control (background) as demonstrated by densitometry. (D) The effect of mutation in the BS5 region on DR5 baseline promoter activity. A498 cells were transfected for 48 h with wild-type or E-box mutant DR5/−1188 promoter constructs. The luciferase activity was measured by using 5 μg of cell protein lysate and values normalized to cotransfected pSV-β-galactosidase plasmid. The luciferase values shown are the mean ± SD from three independent observations.
regulating protein synthesis. Thus, it is also possible that HIF-2α and Myc, MadMyc or both could regulate the DR5 promoter by indirectly controlling the production of proteins that in turn stimulate this promoter. In summary, these data are the first to demonstrate the role of HIF-2α and Myc together in regulating the levels of the TRAIL receptor DR5.

Supplementary material
Supplementary Figures 1–3 can be found at http://carcin.oxfordjournals.org/

Fig. 6. Regulation of DR5 transcription in PV-10 and RCC4 cells. (A) Levels of HIF-2α and Myc, MadMyc after siRNA and pCMVMadMyc transfections into RCC4 cells. RCC4 cells were transfected with siRNA or plasmids. Forty-eight hours later, the cells were homogenized and western blots were carried out. (B) The effect of lowering HIF-2α and Myc levels on DR5 transcription. RCC4 and PV-10 cells were transfected with DR5 (−1188)-Luc and HIF-2α siRNA, Myc siRNA or the Mad/Myc plasmid DNA. Forty-eight hours after transfection, luciferase assays were carried out. The values shown are the mean ± SD from three independent observations. (C) Induction of HIF-2α regulates DR5 levels. Following transfection with the indicated siRNAs for 48 h, A549 lung and PC3 prostate cancer cells were grown at 20 or 0.8% O2. Cells were lysed and subjected to western blot analysis with HIF-2α, DR5 and GAPDH antibodies. (D) siRNA to HIF-1α does not decrease DR5 protein. RCC4 cells were transfected with siRNA to HIF-1α and 48 h later, homogenates were run on sodium dodecyl sulfate–polyacrylamide gel electrophoresis and western blotted for DR5, HIF-2α and HIF-1α. (E) The effect of knock down of HIF-1α on DR5 promoter transcription. RCC4 cells were transfected with DR5 (−1188)-Luc and HIF-1α or HIF-2α siRNA and 48 h after transfection, luciferase assays were carried out. The values shown are the mean ± SD from three independent observations.

**Funding**

National Institutes of Health (R01 CA104710 to A.S.K., P01CA78582 and R01 CA109860 to T.H. and R01 CA128002 to V.D.).

**Acknowledgements**

We are grateful to Dr T. Sakai, Kyoto Prefectural University of Medicine, Kyoto, Japan for the DR5 promoter-luciferase reporter plasmids.
pCMV/MadMyc plasmid was a kind gift from Dr Rene Bernards, The Netherlands Cancer Institute, Amsterdam, The Netherlands. We would also like to acknowledge the Hollings Cancer Center Flow Cytometry and Cell Sorting Core for assistance in these experiments.

Conflict of Interest Statement: None declared.

References

1. Jemal,A., et al (2003) Cancer statistics, 2003. CA Cancer J. Clin., 53, 5–26.
2. Stadler,W.M. (2005) Targeted agents for the treatment of advanced renal cell carcinoma. Cancer, 104, 2323–2333.
3. Stuehler,M., et al (2005) Targeted agents for the treatment of advanced renal cell carcinoma. Curr. Drug Targets, 6, 853–846.
4. Griffith,T.S., et al (2002) Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand (APO-2) ligand-mediated apoptosis in renal cell carcinoma. Cancer Res., 62, 3093–3099.
5. Pitti,R.M., et al (1996) Induction of apoptosis by APO-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem., 271, 12687–12690.
6. Wile,R.K, et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3, 673–682.
7. Walczak,H., et al (2000) The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res., 256, 58–66.
8. Pan,G., et al (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science, 277, 815–818.
9. Sheridan,J.P., et al (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science, 277, 818–921.
10. Zeng,X., et al (2000) Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vivo and inhibits tumor growth in vivo. Int. J. Oncol., 28, 421–430.
11. Zhang,L., et al (2007) Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett., 251, 146–157.
12. Johnson,T.R., et al (2003) The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene, 22, 4953–4963.
13. Nkreda,M., et al (2005) The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol. Cancer Ther., 4, 443–449.
14. Qin,J.Z., et al (2006) Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res., 66, 9636–9645.
15. Zhu,H., et al (2005) Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol. Ther., 4, 781–786.
16. Gnarra,J.R., et al (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet., 7, 85–90.
17. Tsutsumi,H., et al (2003) VHL tumor suppressor gene: its mutation and protein level in renal cell carcinoma. Oncol. Rep., 10, 1357–1361.
18. Wilhelm,M., et al (1995) Terminal deletion of chromosome 3p sequences in nonpapillary renal cell carcinomas: a breakpoint cluster between loci D3S1285 and D3S1603. Cancer Res., 55, 5387–5385.
19. Ivan,M., et al (2001) The von Hippel-Lindau tumor suppressor protein. Curr. Opin. Genet. Dev., 11, 27–34.
20. Maynard,M.A., et al (2003) Multiple splice variants of the human HIF-1 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J. Biol. Chem., 278, 11052–11040.
21. Ohl,M., et al (1998) The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell, 1, 959–968.
22. Hergovich,A., et al (2003) Regulation of microtubule stability by the von Hippel-Lindau tumor suppressor protein pVHL. Nat. Cell Biol., 5, 64–70.
23. Hsu,T., et al (2006) Endoytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 2 (FGFR2). J. Biol. Chem., 281, 12069–12080.
24. Kamada,M., et al (2001) von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility. Cancer Res., 61, 4184–4189.
25. Pioiti,P.A., et al (2001) The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression. J. Biol. Chem., 276, 40346–40352.
26. Krol,S.L., et al (1999) von Hippel-Lindau protein induces hypoxia-regulated arrest of tyrosine hydroxylase transcription elongation in pheochromocytoma cells. J. Biol. Chem., 274, 30109–30114.
27. Qi,H., et al (2003) The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway. Cancer Res., 63, 7076–7080.
28. Kallio,P.J., et al (1999) Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J. Biol. Chem., 274, 6519–6525.
29. Na,X., et al (2003) Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J. Urol., 170, 588–592.
30. Zatka,M., et al (2002) Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res., 62, 3803–3811.
31. Raval,R.R., et al (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol., 25, 5655–5668.
32. Peruzzi,B., et al (2006) The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc. Natl Acad. Sci. USA, 103, 14531–14536.
33. Gordan,J.D., et al (2007) HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell, 11, 335–347.
34. Zhang,H., et al (2007) HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell, 11, 407–420.
35. Yoshida,T., et al (2005) Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res., 65, 5662–5667.
36. Kim,M., et al (1998) Recombinant adenovirus expressing von Hippel-Lindau-mediated cell cycle arrest is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1. Biochem. Biophys. Res. Commum., 253, 672–677.
37. Roc,J.S., et al (2006) p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol. Cell, 22, 395–405.
38. Cui,H., et al (2005) Linking of N-Myc to death receptor machinery in neuroblastoma cells. J. Biol. Chem., 280, 9474–9481.
39. Wang,Y., et al (2004) Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell, 5, 501–512.
40. Davis,N.B., et al (2004) Phase II trial of PS-341 in patients with renal cell cancer; a University of Chicago phase II consortium study. J. Clin. Oncol., 22, 115–119.
41. Kondagunta,G.V., et al (2004) Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J. Clin. Oncol., 22, 3720–3725.
42. Koshiji,M., et al (2004) HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J., 23, 1949–1956.
43. Covello,K.L., et al (2005) Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res., 65, 2277–2286.
44. Hu,C.J., et al (2003) Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell. Biol., 23, 9361–9374.
45. Kim,J.W., et al (2007) HIF-1 and dysregulated c-Myc cooperatively induces VEGF and metabolic switches, HK2 and PDK1. Mol. Cell. Biol., 27, 7381–7393.
46. Nieminen,A.J., et al (2007) c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis. EMBO J., 26, 1055–1067.
47. Ricci,M.S., et al (2007) Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes human cancer cells to TRAIL-induced death. Cancer Cell, 12, 66–80.
48. Gordan,J.D., et al (2007) HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell, 12, 108–113.